Clinical trial · Observational
Omitting of Lymphadenectomy is Acceptable for Lung Cancer Smaller Than 6 mm in Solid Size
NCT06516796CI-TRIAL-00079072completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Many studies suggested that selective lymph node sampling was acceptable for specific non-small cell lung cancer (NSCLC). This study aimed to evaluate the acceptability of omitting of lymphadenectomy for selected NSCLC. Patients with small-sized (≤2 cm) NSCLC who underwent surgical resection between 2009 and 2022 were retrospectively screened.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| No intervention | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- sublobar resection without lymphadenectomy
- description
- Patients received sublobar resection but had no lymphadenectomy
- interventionNames
- Other: No intervention
- label
- sublobar resection with lymphadenectomy
- description
- Patients received sublobar resection plus lymphadenectomy
- interventionNames
- Other: No intervention
- label
- lobectomy plus lymphadenectomy
- description
- Patients received lobectomy plus lymphadenectomy
- interventionNames
- Other: No intervention
Primary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * pathologically confirmed non-small cell lung cancer (NSCLC) * the maximum tumor diameter ≤2 cm * receiving surgical treatment between 2009-2022 Exclusion Criteria: * non-primary NSCLC; * with small cell lung cancer components; * undergoing preoperative neoadjuvant therapies; * with compromised resection; * malignant tumor history over the past five years.
References
Publications (0)
Data not yet available
No reference posted for this study.